Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer

Neil Aj Ryan, Louise Donnelly, Katie Stocking, D Gareth Evans, Emma J Crosbie*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)

8 Downloads (Pure)

Abstract

A barrier to Lynch syndrome testing is the need for prior genetic counselling, a resource demanding process for both patients and healthcare services. We explored the impact of gynaecologist led Lynch syndrome testing in women with endometrial cancer. Women were approached before surgery, on the day of surgery or during routine follow up. Lynch syndrome testing was offered irrespective of age, family history or tumour characteristics. Women's reasons for being tested were explored using the Motivations and Concerns for GeNEtic Testing (MACGNET) instrument. The short form State-Trait Anxiety Inventory (STAI-6) was used to measure anxiety levels. Only 3/305 women declined Lynch syndrome testing. In total, 175/220 completed MACGNET and STAI-6 psychological instruments. The consent process took an average of 7min 36sec (SD 5min 16sec) to complete. The point of care at which consent was taken (before, day of surgery, during follow up) did not influence motivation for Lynch syndrome testing. Anxiety levels were significantly lower when women were consented during follow up (mean reversed STAI-6 score 32 vs 42, p = 0.001). Anxiety levels were not affected by familial cancer history (p = 0.41). Gynaecologist led Lynch syndrome testing is feasible and may even be desirable in endometrial cancer, especially when offered during routine follow up.

Original languageEnglish
Article number1842
Number of pages9
JournalJournal of Clinical Medicine
Volume9
Issue number6
DOIs
Publication statusPublished - 12 Jun 2020

Keywords

  • Lynch syndrome
  • consent
  • anxiety
  • germline testing
  • endometrial cancer

Fingerprint Dive into the research topics of 'Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer'. Together they form a unique fingerprint.

Cite this